Piscataway, NJ, February 25, 2022– Camber Pharmaceuticals is pleased to announce the addition Enalapril Maleate Oral Solution to their current portfolio.
Enalapril Maleate Oral Solution is indicated for the treatment of hypertension, to lower blood pressure in adults and children older than one month.
The 1 mg/mL Enalapril Maleate Oral Solution from Camber is available in 150 mL bottles.
To find out more about Enalapril Maleate Oral Solution please visit https://www.camberpharma.com
Camber Pharmaceuticals is a fully integrated international pharmaceutical company that maintains quality and integrity in all its products. Its parent company, Hetero Drugs of Hyderabad India, is one of the world’s leading API and finished dosage manufacturers. Camber’s commitment to the consumer is to bring the highest quality generic pharmaceuticals to the market to improve quality of life through cost-effective medications.
# # #
If you would like more information about this topic, please contact Megan Little at [email protected].
- Camber Pharmaceuticals Launches Generic Namenda®
- 28 New Generics in 2022 and Anticipates Record Number of Approvals in 2023
- Camber Pharmaceuticals Launches Generic Cambia®
- Camber Pharmaceuticals Launches Generic Kuvan® Tablets and Powder for Oral Solution
- Camber Pharmaceuticals Launches Generic Vimpat® Injection
- Camber Pharmaceuticals Launches Generic Naprosyn®